Drug Profile
VBY 129
Alternative Names: VBY129Latest Information Update: 28 Jan 2019
Price :
$50
*
At a glance
- Originator Unknown
- Developer Virobay
- Class Small molecules
- Mechanism of Action Cathepsin S inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Crohn's disease; Neuropathic pain
- Discontinued Alzheimer's disease; Psoriasis
Most Recent Events
- 28 Jan 2019 No recent reports of development identified for phase-I development in Crohn's-disease in USA (PO)
- 28 Jan 2019 No recent reports of development identified for phase-I development in Neuropathic-pain in USA (PO)
- 10 Dec 2015 Discontinued for Alzheimer's disease in USA (PO)